Request Demo
Last update 20 Jun 2026
Perindopril/Indapamide
Last update 20 Jun 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Biprel, Coverex-AS KombForte, Coversyl Plus + [12] |
Target |
Action inhibitors |
Mechanism ACE inhibitors(Angiotensin-converting enzyme inhibitors), Symporters inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (07 Sep 2005), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS Registry182176-83-6 |
Related
14
Clinical Trials associated with Perindopril/IndapamideCTR20250879
培哚普利吲达帕胺片在健康研究参与者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性试验
[Translation] A randomized, open-label, single-dose, two-period, self-crossover fasting and fed bioequivalence trial of perindopril indapamide tablets in healthy study participants
CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
[Translation] A formal trial of a randomized, open-label, single-dose, two-formulation, two-sequence, crossover controlled design to evaluate the bioequivalence of a single oral dose of the test formulation, perindopril indapamide tablets, and the reference formulation, perindopril indapamide tablets (trade name: Bipro®) in healthy Chinese subjects under fasting and fed conditions
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
[Translation] A randomized, open-label, single-dose, two-period, self-crossover bioequivalence study of perindopril indapamide tablets in healthy subjects under fasting and fed conditions
100 Clinical Results associated with Perindopril/Indapamide
Login to view more data
100 Translational Medicine associated with Perindopril/Indapamide
Login to view more data
100 Patents (Medical) associated with Perindopril/Indapamide
Login to view more data
175
Literatures (Medical) associated with Perindopril/Indapamide01 May 2026DIABETES OBESITY & METABOLISM
Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the
ADVANCE
Study
Article
Author: Zhang, Yonghong ; Gao, Yijie ; Chen, Xiaoying ; Marre, Michel ; Harrap, Stephen ; Mancia, Giuseppe ; Woodward, Mark ; Wang, Ruirui ; Anderson, Craig S. ; Peters, Ruth ; Hamet, Pavel ; Harris, Katie ; Chalmers, John ; Chen, Linan
ABSTRACT:
Aims:
To determine the association of insulin resistance, assessed using the estimated glucose disposal rate (eGDR), and the risk of adverse clinical outcomes, and determine any effect modification on the efficacy of glucose‐ and blood pressure (BP)‐lowering treatments.
Materials and Methods:
Briefly, 11 140 participants with type 2 diabetes (T2D) were recruited from 20 countries for the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. eGDR was derived from waist circumference, hypertension status and glycated haemoglobin, calculated in 11 081 participants. Multivariable Cox models were used to estimate hazard ratios (HRs) of the association of eGDR with clinical events.
Results:
Over a median of 5 years of follow‐up, 2117 participants (19.1%) experienced a major macrovascular or microvascular event. Compared with individuals in the lowest quarter of eGDR, those in the highest quarter had significantly lower risks of a composite major macrovascular and microvascular event (HR 0.72, 95% CI 0.62–0.84). Similar associations were seen for major macrovascular events (HR 0.68, 95% CI 0.55–0.85), major microvascular events (HR 0.78, 95% CI 0.63–0.96), all‐cause mortality (HR 0.69, 95% CI 0.55–0.86), and cardiovascular mortality (HR 0.62, 95% CI 0.45–0.85). No significant effect modification was observed across eGDR quarters for the efficacy or safety of intensive glucose control (vs. standard control) or BP–lowering treatment (vs. placebo).
Conclusion:
These findings highlight the value of eGDR as a prognostic marker for T2D. Intensive glucose‐ and BP‐lowering treatments remain beneficial regardless of insulin resistance status.Trial Registration:ClinicalTrials.gov
identifier: NCT00145925
07 Apr 2026Journal of the American Heart Association
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial
Article
Author: Shajahan, Sultana ; MacMahon, Stephen ; Mancia, Giuseppe ; Anderson, Craig S ; Peters, Ruth ; Harris, Katie ; Woodward, Mark ; Harrap, Stephen ; Chalmers, John ; Tully, Phillip J ; Wang, Nelson ; Carcel, Cheryl ; Poulter, Neil
Background:
Blood pressure (BP) variability and cumulative BP load are significantly associated with cardiovascular disease risk beyond mean systolic BP, but less is known regarding their associations with cognitive decline/dementia and whether these associations differ by cognitive function at baseline or by sex. The aims of this study were to determine associations of different BP parameters with cognitive decline/dementia in patients with type 2 diabetes and explore differences by mild cognitive impairment at baseline and sex.
Methods:
Using data from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study, BP parameters were calculated from an 18‐month exposure window comprising measurements at 3, 4, 6, 12, and 18 months, after randomization. Logistic regression was used to estimate the odds ratio (OR) per SD higher and 95% CI for the associations of BP parameters with the composite outcome of cognitive decline (≥3 points from baseline on the Mini‐Mental State Examination) or clinical diagnosis of dementia.
Results:
Of the 11 140 ADVANCE participants, 9586 patients had 5 complete BP measurements within the 18‐month exposure window. After a mean follow‐up of 3.5 years, 1674 (17.5%) participants were diagnosed with cognitive decline and/or dementia. Overall, variability and baseline pulse pressure (PP), but not BP load, were associated with higher odds of cognitive decline/dementia (OR: variability in systolic BP, 1.11 [95% CI, 1.05–1.17]; diastolic BP, 1.11 [95% CI, 1.05–1.17]; PP, 1.05 [95% CI, 1.00–1.11]; mean arterial pressure, 1.13 [95% CI, 1.07–1.19]; and baseline PP, 1.19 [95% CI, 1.13–1.25]). There were no differences by mild cognitive impairment at baseline or sex.
Conclusions:
Higher BP variability and baseline PP, but not mean BP or BP load, were associated with higher odds of cognitive decline/dementia in patients with type 2 diabetes. BP variability and PP may be important therapeutic markers for the preservation of brain health.
Registration:
URL:
https://clinicaltrials.gov
; Unique Identifier: NCT00145925.
01 May 2025BMJ Open Diabetes Research & Care
Relationship between time-varying achieved HbA1c and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study
Article
Author: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Chalmers, John ; Selvin, Elizabeth ; Warren, Rachel A ; Lavallée, Samantha K ; Rimm, Eric ; Levy, Andrew P ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
Introduction:
This study sought to determine whether the association between attaining specific glycated hemoglobin (HbA1c) targets (<7.0% (<53 mmol/mol) and ≥8.0% (≥64 mmol/mol) compared with 7.0%–7.9%) over time and risk of incident coronary artery disease (CAD) was dependent on haptoglobin (Hp) phenotype in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study.
Research design and methods:
Prospectively collected HbA1c data from the ADVANCE biomarker case-cohort study, updated at 6 months and every 12 months thereafter over a median of 5.0 (IQR 4.5–5.3) years, were analyzed in relation to incident CAD in the Hp2-2 (n=1323) and non-Hp2-2 (n=2069) phenotypes separately using weighted multivariable-adjusted Cox regression models. Additional a priori stratifications by sex, race, previous cardiovascular disease (CVD), and type 2 diabetes duration were performed.
Results:
Mean HbA1c was similar in each phenotype group throughout the study. Compared with HbA1c of 7.0%–7.9%, HbA1c <7.0% was not associated with CAD risk for any phenotype group or subgroup. HbA1c ≥8.0% compared with 7.0%–7.9% over time was associated with higher CAD risk for the Hp2-2 phenotype only (HR 1.53, 95% CI 1.01 to 2.32; no significant association in the non-Hp2-2 type: 1.26, 0.89 to 1.77, p-interaction=0.71); this was pronounced when those with previous CVD at baseline were excluded (Hp2-2: 2.80, 1.41 to 5.53, p-interaction=0.03). Compared with HbA1c of <8.0%, having HbA1c ≥8.0% was associated with a 59% higher CAD risk among participants with the Hp2-2 phenotype (1.59, 1.12 to 2.26) and a 39% higher CAD risk among participants without the Hp2-2 phenotype (1.39, 1.03 to 1.88, p-interaction=0.97).
Conclusions:
The present ADVANCE analysis suggests that not having HbA1c ≥8.0%, rather than achieving HbA1c <7.0%, was found to be particularly important for CAD prevention among people with type 2 diabetes and the common Hp2-2 phenotype. While the subgroup analyses were likely underpowered, their inclusion is hypothesis generating and can be used in future meta-analyses to improve power and generalizability.
100 Deals associated with Perindopril/Indapamide
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypertension | China | 07 Sep 2005 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Angina, Unstable | Phase 3 | China | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Australia | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Canada | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Netherlands | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | United Kingdom | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | China | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Australia | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Canada | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Netherlands | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | United Kingdom | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | - | Active BP lowering treatment (combination perindopril±indapamide) | exksaklicm(jfvasytkzg) = vbyouthwot jgcoamfite (vsaeckoawx ) | - | 01 Mar 2023 | ||
Placebo | exksaklicm(jfvasytkzg) = ngmjuuzcfy jgcoamfite (vsaeckoawx ) | ||||||
Phase 3 | 9,694 | dcpiseikwz(gigyjtjpvo): 0.91 (95% CI, 0.83 - 1.0), P-Value = 0.04 | - | 01 Aug 2022 | |||
Placebo | |||||||
Phase 3 | 682 | (Intensive blood glucose control) | cmbxqhhhwo(fvkngscwik) = njhdcnbaly tfnjsxduuf (mobtvhanik, -20.2%, - 0.9%) View more | - | 16 Apr 2022 | ||
(Intensive blood pressure control) | ddxhmcutup(iqxaxrpzvn) = gmksztwcar cctmxbqxda (oztwxkbokb, -8.9 to 3.6) | ||||||
Phase 3 | 11,140 | mybuobugnk(wgqynhzist) = lrfhewoyra hpcdwbxldi (banghspbxx, 6.15 - 10.63) | - | 25 May 2021 | |||
Phase 3 | 11,140 | xhdxyeotne(wsdmxcvdng): 0.78 (95% CI, 0.71 - 0.86) | - | 20 Apr 2021 | |||
Placebo | |||||||
Phase 3 | 9,195 | (³30% decrease in UACR) | dspymqktmt(bzrfvsjpts): HR = 0.1 (95% CI, 0.01 - 0.79) | Positive | 03 Nov 2015 | ||
(<30% decrease to <30% increase in UACR) | |||||||
Not Applicable | - | cfgxoyiesy(uybqtasxdm): 0.91 (95% CI, 0.84 - 0.99), P-Value = 0.03 | - | 09 Oct 2014 | |||
Placebo | |||||||
Phase 3 | 11,140 | (Normal cognitive function) | hsdwpblksh(ejfphccjbr): HR = 1.33 (95% CI, 1.16 - 1.54), P-Value = < 0.03 View more | - | 01 Nov 2009 | ||
(Mild cognitive dysfunction) | |||||||
Phase 3 | - | dzsmioalrt(fakevhiecs) = hyotbatszl eonbpabual (tughrndbef, 12 - 50) | - | 01 Nov 2009 | |||
oypapbeygk(zzvqubqasd) = fxgklgdhqm dtbkhdejqc (jfafvaglng, 1 - 32) View more | |||||||
Phase 3 | 11,140 | dxwreftdcu(neehkndsdo) = toenmvmiqn asjtzfhuif (yaebrhohox ) | - | 08 Sep 2007 | |||
Placebo | dxwreftdcu(neehkndsdo) = sfszewyxta asjtzfhuif (yaebrhohox ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free